RESEARCH EXPERIMENT

ABM/2022/3

A single-center, randomized, open-label study to evaluate the safety and efficacy of renal artery denervation therapy with atrial fibrillation ablation in patients with atrial fibrillation and heart failure.

CRO
BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
666-069-834
[email protected] BioStat CBR
Sponsor
Górnośląskie Centrum Medyczne
im. prof. Leszka Gieca
Śląskiego Uniwersytetu Medycznego
w Katowicach

ul. Ziołowa 45-47,
40-635 Katowice BioStat CBR

Ladies and Gentlemen,

 

We invite you to participate in a single-center, randomized, open-label research experiment aimed at evaluating the safety and efficacy of renal artery denervation therapy with atrial fibrillation ablation in patients with atrial fibrillation and heart failure.